Publications

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.

Uptake of screening services, turnaround times and results

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Isatuximab in combination with bortezomib, lenalidomide and dexamethasone as a first-line treatment for adult patients with newly diagnosed multiple myeloma, who are ineligible for an autologous stem cell transplant (ASCT) (SMC2804) is being assessed for use by NHSScotland.

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.

The aim of this work was to capture real-world evidence from Scotland on the use of maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) Systemic Anti-Cancer Therapy (SACT) of adult patients with advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, following completion of first-line platinum-based chemotherapy. The Scottish Medicines Consortium (SMC) requested this work which describes current SACT use in this population. This work will assist SMC members when considering submissions for rucaparib (SMC2799).

About this release This release by Public Health Scotland (PHS) uses information from the National SACT dataset. This work was requested by the National Cancer Medicines Advisory...

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.

This release by Public Health Scotland (PHS) reports on systemic anti-cancer therapy (SACT) activity across NHS services in Scotland. Treatment activity includes the weekly number of appointments and the monthly and annual number of appointments and patients receiving treatment.